Fig. 4From: Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective studySurvival rate of patients with different underlying diseases within 9-year follow-up. At 5-year follow up, survival rates for different diseases were ordered from highest priority to lowest as follows: RA, SLE, SS, SSc, and PM/DMBack to article page